STOCK TITAN

Arrowhead Pharmaceuticals Inc. - ARWR STOCK NEWS

Welcome to our dedicated news page for Arrowhead Pharmaceuticals (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arrowhead Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arrowhead Pharmaceuticals's position in the market.

Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. hosted an R&D Day to discuss progress towards its goal of having 20 clinical stage or marketed products by 2025. The company highlighted advancements in its TRiM platform, including improved knockdown of target genes and expanded delivery to different cell types. Presentations were given on various programs, including CNS, pulmonary, liver-targeted, and cardiometabolic programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.64%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Arrowhead Pharmaceuticals Inc.

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

2.93B
118.95M
4.49%
66.68%
7.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Pasadena

About ARWR

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing